Effect of cancer on outcome of COVID-19 patients: a systematic review and meta-analysis of studies of unvaccinated patients

• Published in: eLife Vol. 11
• Main Authors: Di Felice, Giulia, Visci, Giovanni, Teglia, Federica, Angelini, Marco, Boffetta, Paolo
• Format: Journal Article
• Language: English
• Published: England eLife Sciences Publications Ltd 16-02-2022; eLife Sciences Publications, Ltd
• Subjects: Cancer; Cancer Biology; Coronaviruses; COVID-19; COVID-19 vaccines; disease severity; Epidemiology and Global Health; Hospitalization; Immunization; Infections; Meta-analysis; Mortality; SARS-CoV-2; Sensitivity analysis; Severe acute respiratory syndrome coronavirus 2; Systematic review; Iran; United States > US; China; Spain; COVID-19; global health; epidemiology; SARS-CoV-2; meta-analysis; mortality; cancer; cancer biology; disease severity; human
• ISSN: 2050-084X; 2050-084X
• DOI: 10.7554/eLife.74634

Since the beginning of the SARS-CoV-2 pandemic, cancer patients affected by COVID-19 have been reported to experience poor prognosis; however, a detailed quantification of the effect of cancer on outcome of unvaccinated COVID-19 patients has not been performed.
To carry out a systematic review of the studies comparing the outcome of unvaccinated COVID-19 patients with and without cancer, a search string was devised which was used to identify relevant publications in PubMed up to December 31, 2020. We selected three outcomes: mortality, access to ICU, and COVID-19 severity or hospitalization. We considered results for all cancers combined as well as for specific cancers. We conducted random-effects meta-analyses of the results, overall and after stratification by region. We also performed sensitivity analyses according to quality score and assessed publication bias.
For all cancer combined, the pooled odds ratio (OR) for mortality was 2.32 (95% confidence interval [CI] 1.82-2.94, I
for heterogeneity 90.1%, 24 studies), that for ICU admission was 2.39 (95% CI 1.90-3.02, I
0.0%, 5 studies), that for disease severity or hospitalization was 2.08 (95% CI 1.60-2.72, I
92.1%, 15 studies). The pooled mortality OR for hematologic neoplasms was 2.14 (95% CI 1.87-2.44, I
20.8%, 8 studies). Data were insufficient to perform a meta-analysis for other cancers. In the mortality meta-analysis for all cancers, the pooled OR was higher for studies conducted in Asia than studies conducted in Europe or North America. There was no evidence of publication bias.
Our meta-analysis indicates a twofold increased risk of adverse outcomes (mortality, ICU admission, and severity of COVID-19) in unvaccinated COVID-19 patients with cancer compared to COVID-19 patients without cancer. These results should be compared with studies conducted in vaccinated patients; nonetheless, they argue for special effort to prevent SARS-CoV-2 infection in patients with cancer.
No external funding was obtained.